These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3050410)

  • 1. Naftifine for fungal skin infections.
    Med Lett Drugs Ther; 1988 Oct; 30(777):98-9. PubMed ID: 3050410
    [No Abstract]   [Full Text] [Related]  

  • 2. Naftifine cream in the treatment of cutaneous candidiasis.
    Zaias N; Astorga E; Cordero CN; Day RM; de Espinoza ZD; DeGryse R; Rojas RF; Sefton J
    Cutis; 1988 Sep; 42(3):238-40. PubMed ID: 3048914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing topical antifungal therapy for superficial cutaneous fungal infections: focus on topical naftifine for cutaneous dermatophytosis.
    Del Rosso JQ; Kircik LH
    J Drugs Dermatol; 2013 Nov; 12(11 Suppl):s165-71. PubMed ID: 24196340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of once- and twice-daily naftifine cream regimens with twice-daily clotrimazole in the treatment of tinea pedis.
    Smith EB; Wiss K; Hanifin JM; Jordon RE; Rapini RP; Lasser AE; Kirschenbaum MB; Millikan LE; Parish LC; Rapaport MJ
    J Am Acad Dermatol; 1990 Jun; 22(6 Pt 1):1116-7. PubMed ID: 2370340
    [No Abstract]   [Full Text] [Related]  

  • 5. [The antifungal agent naftifin. Placebo-controlled therapeutic comparison in tinea pedis].
    Klaschka F; Gartmann H; Weidinger G
    Z Hautkr; 1984 Sep; 59(18):1218-26. PubMed ID: 6388170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftifine HCl Gel 2% in Pediatric Subjects With Tinea Pedis.
    Verma A; Olayinka B; Fleischer AB
    J Drugs Dermatol; 2015 Jul; 14(7):686-91. PubMed ID: 26151784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Naftifine HCl Cream 2% in the Treatment of Pediatric Subjects With Tinea Corporis.
    Gold M; Dhawan S; Verma A; Kuligowski M; Dobrowski D
    J Drugs Dermatol; 2016 Jun; 15(6):743-8. PubMed ID: 27272083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label study of naftifine hydrochloride 1% gel in the treatment of tinea versicolor.
    Gold MH; Bridges T; Avakian E; Plaum S; Pappert EJ; Fleischer AB; Hardas B
    Skinmed; 2011; 9(5):283-6. PubMed ID: 22165042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily naftifine cream 1% in the treatment of tinea cruris and tinea corporis.
    Jordon RE; Rapini RP; Rex IH; Katz HI; Hickman JG; Bard JW; Medansky RS; Lew-Kaya DA; Sefton J; DeGryse RE
    Int J Dermatol; 1990; 29(6):441-2. PubMed ID: 2397973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naftifine cream 1% versus econazole cream 1% in the treatment of tinea cruris and tinea corporis.
    Millikan LE; Galen WK; Gewirtzman GB; Horwitz SN; Landow RK; Nesbitt LT; Roth HL; Sefton J; Day RM
    J Am Acad Dermatol; 1988 Jan; 18(1 Pt 1):52-6. PubMed ID: 3279083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Double blind, randomized in vivo investigations comparing the antifungals clotrimazole, tolnaftate and naftifine (author's transl)].
    Hantschke D; Reichenberger M
    Mykosen; 1980 Dec; 23(12):657-68. PubMed ID: 7012610
    [No Abstract]   [Full Text] [Related]  

  • 12. Naftifine: a topical allylamine antifungal agent.
    Mühlbacher JM
    Clin Dermatol; 1991; 9(4):479-85. PubMed ID: 1822408
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind comparison of naftifine cream and clotrimazole/betamethasone dipropionate cream in the treatment of tinea pedis.
    Smith EB; Breneman DL; Griffith RF; Hebert AA; Hickman JG; Maloney JM; Millikan LE; Sulica VI; Dromgoole SH; Sefton J
    J Am Acad Dermatol; 1992 Jan; 26(1):125-7. PubMed ID: 1732321
    [No Abstract]   [Full Text] [Related]  

  • 14. Development, optimization and characterization of nanoemulsion loaded with clove oil-naftifine antifungal for the management of tinea.
    Alghaith AF; Alshehri S; Alhakamy NA; Hosny KM
    Drug Deliv; 2021 Dec; 28(1):343-356. PubMed ID: 33517791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allylamines: topical and oral treatment of dermatomycoses with a new class of antifungal agents.
    Ganzinger U; Stutz A; Petranyi G; Stephen A
    Acta Derm Venereol Suppl (Stockh); 1986; 121():155-60. PubMed ID: 3459341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contact allergy to the antifungal agent naftifin].
    Hoting E; Küchmeister B; Hausen BM
    Derm Beruf Umwelt; 1987; 35(4):124-7. PubMed ID: 2959458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Naftifine solution (1%) in the treatment of pityriasis versicolor in Zambia.
    Hira SK; Abraham MS; Mwinga A; Kamanga J; Schmidt C
    Mykosen; 1986 Aug; 29(8):378-81. PubMed ID: 3531847
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evaluation of the efficacy of a new antimycotic molecule for topical use: naftifine].
    Albanese G; Giorgetti P; Santagostino L; Di Cintio R; Colombo MD
    G Ital Dermatol Venereol; 1989 May; 124(5):XXXIII-XXXVII. PubMed ID: 2620916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and relevance of naftifine hydrochloride in the stratum corneum up to four weeks following the last application of naftifine cream and gel, 2%.
    Plaum S; Verma A; Fleischer AB; Olayinka B; Hardas B
    J Drugs Dermatol; 2013 Sep; 12(9):1004-8. PubMed ID: 24002147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo cutaneous penetration and antifungal activity of naftifine.
    Stoughton RB; Sefton J; Zeleznick L
    Cutis; 1989 Oct; 44(4):333-5. PubMed ID: 2805810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.